Posted by Michael Wonder on 19 Apr 2023
SAB Biotherapeutics announces US FDA grants breakthrough therapy designation to SAB-176 influenza immunotherapy
18 April 2023 - SAB-176 has now received both breakthrough and fast track designations from FDA – signifying its potential to fundamentally improve influenza treatment and prophylaxis.
SAB Biotherapeutics announced today that the US FDA has granted breakthrough therapy designation to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.
